The worldwide expression proteomics market has prospects for huge development. This is due to increasing consciousness among people regarding custom-made medicines and consequent rise in the applications of pharmaceutical industrial developments based on proteomic technologies.
However, diminished research finances in the market of the United States and challenges encountered by various proteomics companies to get authoritarian sanctions for biomarkers prevent the expression proteomics market from improving further.
Lack of competent research specialists and soaring prices of proteomic devices also slow down the market. North America leaded the worldwide expression proteomics market in 2013 and will continue to do so till 2018.